Nonoperative Management of Rectovaginal Fistula
Observation, symptom control and treatment of the underlying disease can precede or accompany rectovaginal fistula (RVF) repair. Seton placement and fecal diversion are procedural or surgical adjuncts, not medical treatments. Their purpose may be drainage or symptom relief rather than definitive fistula closure.
See Rectovaginal Fistula, ERAF ± Sphincteroplasty and Fecal Diversion for evaluation and operative options.
Conservative care and reassessment
ASCRS 2022 supports initial nonoperative care for most obstetric RVFs and selected benign, minimally symptomatic fistulas (2C). Measures include local hygiene, baths, wound care, debridement when needed, stool-bulking fiber and antibiotics for infection. A 3–6-month period is typical in suitable patients; the reported 52–66% healing comes from selected observational evidence, not a universal prognosis. Symptoms and tissue recovery should determine reassessment rather than a mandatory waiting period.[1]
A small opening can coexist with a deeper infected cavity. Worsening pain, fever or suspected abscess requires prompt assessment and source control; observation is not a reason to postpone drainage. Suspected malignancy requires diagnosis and an oncologic plan before choosing a benign fistula repair.[1][2]
Drainage and setons
A loose draining seton may reduce or prevent infection in a narrow tract, a small vaginal opening or multiple tracts, and can provide longer-term symptom relief when repair is unsuitable. It is not required for every RVF and may leave ongoing drainage.[1]
Multidisciplinary examination under anesthesia can clarify the tract, associated defects and rectal disease. A published technical demonstration describes curettage and subsequent seton placement; it does not establish a comparative closure rate or justify routine traumatic instrumentation.[3]
Crohn's disease: control sepsis and inflammation
Coordinate colorectal surgery, gastroenterology and urogynecology. Drain infection when present, assess rectal inflammation and strictures, and optimize medical treatment. Control of proctitis is important before elective closure; it is not a prerequisite for urgent abscess drainage. ECCO 2024 suggests medical treatment and consideration of surgical closure in selected anogenital or rectogenital fistulas; the specific supporting evidence is low level.[4]
ACG 2025 notes that internal fistulas, including RVF, have limited trial evidence. Infliximab with or without an immunomodulator is commonly used before selected repair; the guideline does not require an immunomodulator for every patient. Drug selection, safety screening, dosing and monitoring belong in a gastroenterology-directed plan.[2]
Distinguish RVF evidence from perianal-fistula evidence
| Evidence | What it supports—and its limits |
|---|---|
| ACCENT II RVF post hoc analysis | Twenty-five women had 27 draining RVFs at baseline. After infliximab induction, 13/29 evaluated fistulas were closed at week 14; the evolving denominators count fistulas, not women. Median closure duration was 46 weeks with maintenance infliximab versus 33 with placebo. This small subgroup supports a possible medical response, not guaranteed durable closure.[5] |
| AGA 2021, active perianal fistula | Recommends infliximab; suggests adalimumab, ustekinumab or vedolizumab. In patients without a perianal abscess, it recommends a biologic plus an antibiotic over biologic alone and suggests against antibiotics alone. These recommendations are explicitly for perianal fistulas; their strength should not be relabeled as RVF-specific evidence.[6] |
| Seton plus medical therapy | Drainage and biologic treatment are complementary when sepsis is present. The often-quoted 46% versus 13% comparison in the ASCRS discussion is anti-TNF versus placebo from a perianal-fistula trial subgroup, not a randomized estimate of the added benefit of a seton in RVF.[1] |
Antibiotics can treat infection and may be adjunctive to biologics. The ACG discussion of multiweek metronidazole or fluoroquinolone regimens for simple perianal fistulas should not become a default prescription for every RVF. An abscess generally needs drainage; repeated antibiotics alone do not correct the underlying anatomy.[2]
Fecal diversion: a separate decision
Diversion may help manage an anastomotic complication, substantial contamination, severe refractory Crohn's disease or distressing symptoms. It can also accompany a planned repair. For an early anastomotic RVF, selected patients may instead require reoperation and reconstruction; a single fixed pathway is inappropriate.[1][2]
In Obi's 2026 retrospective cohort, 158 women underwent 424 procedures: 100 were diverted and 58 were not. Five-year estimated cure was 72.7% versus 64.3% (P = .38). Patients with repeated repairs were more likely to be diverted, so these results do not prove that diversion improves cure or equalizes risk.[7]
For radiation-associated RVF, diversion can relieve symptoms without closing the fistula. Selected restorative resections or permanent diversion require separate assessment of morbidity and function; see Transabdominal RVF Repair.
Adjuncts with limited evidence
- Fibrin glue and plugs: ASCRS excludes them from its RVF repair recommendations because reported results are poor. A historical glue series healed 4/5 RVFs, but only 6/10 fistulas overall; this tiny mixed series does not establish reliable efficacy.[1][8]
- Vaginal estrogen: one pessary-associated RVF closed after pessary removal plus estradiol, so the estrogen effect cannot be isolated. Treating symptomatic atrophy is a different goal from claiming that estrogen closes a fistula.[9]
- Experimental healing strategies: a menopausal-rat vaginal-injury study found different epithelial and stromal responses to postoperative estrogen. It was not a human RVF trial and does not establish either clinical benefit or harm in this setting. Microbiome-directed fistula treatment remains investigational.[10][11]
Elective repair is considered when persistent drainage or functional burden outweighs continued conservative care, after addressing the cause, infection, tissue quality and patient preferences. Closure, continence, sexual function and the possibility of retaining a stoma should be discussed separately.
References
1. Gaertner WB, Burgess PL, Davids JS, et al. The American Society of Colon and Rectal Surgeons clinical practice guidelines for the management of anorectal abscess, fistula-in-ano, and rectovaginal fistula. Dis Colon Rectum. 2022;65(8):964–985. doi:10.1097/DCR.0000000000002473
2. Lichtenstein GR, Loftus EV, Afzali A, et al. ACG clinical guideline: management of Crohn's disease in adults. Am J Gastroenterol. 2025;120(6):1225–1264. doi:10.14309/ajg.0000000000003465
3. Muñoz JM, Levin PJ, Saur NM, Cox CK. Multidisciplinary approach to evaluation of rectovaginal fistulas. Am J Obstet Gynecol. 2024;231(2):285–286. doi:10.1016/j.ajog.2024.04.029
4. Adamina M, Minozzi S, Warusavitarne J, et al. ECCO guidelines on therapeutics in Crohn's disease: surgical treatment. J Crohns Colitis. 2024;18(10):1556–1582. doi:10.1093/ecco-jcc/jjae089
5. Sands BE, Blank MA, Patel K, van Deventer SJ; ACCENT II Study. Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol. 2004;2(10):912–920. doi:10.1016/S1542-3565(04)00414-8
6. Feuerstein JD, Ho EY, Shmidt E, et al. AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn's disease. Gastroenterology. 2021;160(7):2496–2508. doi:10.1053/j.gastro.2021.04.022
7. Obi M, Kanters A, Spivak AR, et al. Determinants of fecal diversion prior to rectovaginal fistula surgery. J Gastrointest Surg. 2026:102442. doi:10.1016/j.gassur.2026.102442
8. Abel ME, Chiu YS, Russell TR, Volpe PA. Autologous fibrin glue in the treatment of rectovaginal and complex fistulas. Dis Colon Rectum. 1993;36(5):447–449. doi:10.1007/BF02050009
9. Cichowski S, Rogers RG. Nonsurgical management of a rectovaginal fistula caused by a Gellhorn pessary. Obstet Gynecol. 2013;122(2 Pt 2):446–449. doi:10.1097/AOG.0b013e31828aec98
10. Ripperda CM, Maldonado PA, Acevedo JF, et al. Vaginal estrogen: a dual-edged sword in postoperative healing of the vaginal wall. Menopause. 2017;24(7):838–849. doi:10.1097/GME.0000000000000840
11. Satora M, Żak K, Frankowska K, et al. Perioperative factors affecting the healing of rectovaginal fistula. J Clin Med. 2023;12(19):6421. doi:10.3390/jcm12196421